North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency

Size: px
Start display at page:

Download "North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency"

Transcription

1 North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.

2 This study is sponsored by major grants from: Novartis Pharmaceutical Corporation AMGEN Inc. Genentech, Inc. NAPRTCS also thanks the following contributors: Roche Laboratories, Inc. Wyeth Research Watson Pharmaceuticals

3 North American Pediatric Renal Transplant Cooperative Study Clinical Coordinating Center Data Coordinating Center William Harmon, M.D. Donald Stablein, Ph.D. NAPRTCS Lynya Talley, Ph.D. 1 Autumn Street The EMMES Corporation 5th Floor 401 N. Washington Street, Suite 700 Boston, Massachusetts Rockville, Maryland Board Members William Harmon, MD (President) Richard Fine, MD (Vice President/Treasurer) Steven Alexander, MD (Secretary) Bradley Warady, MD (Member at Large) Mark Benfield, MD (Member at Large) Stuart Goldstein, MD (Chair, PCC) Ruth McDonald, MD (Chair, Special Studies Committee and Vice-Chair, PCC)

4 This report was developed under the auspices of the Operations Committee and prepared by Lynya Talley, Ph.D. and Donald M. Stablein, Ph.D. With assistance from Data Coordinating Center Staff Stuart Berlin Angela Norman Kumar Thotapally Danielle Weidenhamer-Quarles

5 TABLE OF CONTENTS PAGE I INTRODUCTION 1 II TRANSPLANTATION Section 1: Transplant Patient Characteristics 1-1 Section 2: Donor History and Antigen Mismatches 2-1 Section 3: Therapy 3-1 Section 4: Rejection 4-1 Section 5: Graft Function 5-1 Section 6: Growth 6-1 Section 7: Morbidity, Malignancy, and Mortality 7-1 III DIALYSIS Section 8: Dialysis Patient Characteristics 8-1 Section 9: Dialysis Access Data 9-1 Section 10: Erythropoietin Use in Dialysis Patients 10-1 Section 11: Dialysis Follow-up 11-1 Section 12: Growth 12-1 IV CHRONIC RENAL INSUFFICIENCY Section 13: CRI Patient Demographics 13-1 Section 14: Termination of Chronic Renal Insufficiency Status 14-1 Section 15: CRI Follow-up Data 15-1 V APPENDICES Appendix A: Participating Centers and Contact Physicians A-1 Appendix B: Bibliography C B-1 Appendix C: Special Studies and Analyses C-1 i

6 LIST OF EXHIBITS Section 1 Exhibit 1.1 Patient Registrations, Transplants, and Selected Characteristics, by Year of Registration 1-4 Exhibit 1.2 Recipient and Index Transplant Characteristics 1-5 Exhibit 1.3 Transplant Characteristics 1-6 Exhibit 1.4 Age at Transplantation 1-7 Exhibit 1.5 Age at Index Transplant, by Patient's Sex, Race, and Diagnosis 1-8 Exhibit 1.6 Sex, Race, and Biopsy Distributions, by Primary Renal Diagnosis 1-9 Exhibit 1.7 Primary Diagnosis by Age 1-10 Section 2 Exhibit 2.1 Donor Information 2-3 Exhibit 2.2 Use Over Time of Donor-Specific and Random Blood Transfusions 2-4 Exhibit 2.3 Percent HLA Mismatches 2-5 Exhibit 2.4 Age at Transplant and Donor Source 2-6 Section 3 Exhibit 3.1 Medication Data First 30 Days, Transplants after Exhibit 3.2 Week 1 Calcineurin Inhibitor Use, by Induction Antibody 3-6 Exhibit 3.3 Induction Antibody Use, by Year 3-6 Exhibit 3.4 Exhibit 3.5 Exhibit 3.6 Exhibit 3.7 Mean (SE) Daily Drug Dosages, by Drug Combination and Year Post-Transplant 3-7 Percent of Patients with Functioning Grafts Receiving Immunosuppressive Medication 30 Days Post Transplant, by Year of Transplant 3-8 Percentage of Patients Receiving Designated Maintenance Immunosuppression Regimens, by Donor Source and Time of Follow-up 3-9 Percentage of Patients Receiving Concomitant Medications, by Donor Source and Time Post-Transplantation 3-10 ii

7 Section 4 Exhibit 4.1A Frequency of Acute Rejections 4-4 Exhibit 4.1B Acute Rejection Ratios 4-4 Exhibit 4.2 Time to First Rejection Episode, by Allograft Source and Transplant Year 4-5 Exhibit 4.3A Exhibit 4.3B Relative Hazard (RH) of First Rejection Episode, First Transplant, Relative Hazard (RH) of First Rejection Episode, First Transplant, Exhibit 4.4 Time to First Rejection Episode, by Selected Characteristics 4-8 Exhibit 4.5A Rejection Reversal Outcome by Selected Characteristics 4-10 Exhibit 4.5B Rejection Reversal Outcome by Selected Characteristics for First Acute Rejection Episode Only 4-11 Exhibit 4.6 Rejection Reversal Outcome by Transplant Year 4-12 Exhibit 4.7 Summary of Late First Rejections, by Selected Characteristics 4-13 Section 5 Exhibit 5.1 Causes of Graft Failure 5-7 Exhibit 5.2 Percent Graft Survival by Allograft Source 5-8 Exhibit 5.3 Graft Failure Summary, by Allograft Source and Transplant Characteristics 5-9 Exhibit 5.4 Percent Graft Survival for Recipients of Living Donor Source Allografts 5-11 Exhibit 5.5 Percent Graft Survival for Recipients of Cadaver Donor Source Allografts 5-12 Exhibit 5.6 Percent Graft Survival for Annual Cohort Group 5-14 Exhibit 5.7 Graft Survival by Donor Source and HLA-Antigen Disparity 5-15 Exhibit 5.8 Percent Graft Survival, by Donor Source and Diagnosis 5-16 Exhibit 5.9 Exhibit 5.10 Exhibit 5.11 Post Week 1 Graft Survival by Donor Source and Acute Tubular Necrosis Status 5-17 Serial Serum Creatinine and Calculated Creatinine Clearance Measures for Functioning Grafts, by Age at Transplant 5-18 Serial Serum Creatinine for Functioning Grafts, by Race and Induction Antibody Therapy 5-19 iii

8 Exhibit 5.12 Exhibit 5.13 Exhibit 5.14 Graft Function, i.e. Graft Survival and Mean Calculated Clearance at Annual Follow-up, by Donor Source 5-20 Graft Function, i.e. Graft Survival and Mean Calculated Clearance at Annual Follow-up, by Donor Source and Initial Use of Antibody Preparations 5-21 Graft Function, i.e. Graft Survival and Mean Calculated Clearance at Annual Follow-up, by Donor Source and Race 5-22 Section 6 Exhibit 6.1 Exhibit 6.2 Exhibit 6.3 Exhibit 6.4 Mean (with SE) Standardized Height and Weight Scores, by Selected Characteristics and Times Post-Transplantation 6-3 Mean Change from Baseline (with SE) in Standardized Height and Weight Scores in Subjects with Graft Function, by Age at Transplant 6-4 Mean (with SE) of Standardized Height at Time of Initial Transplant, by Year of Transplant 6-5 Mean (with SE) of Standardized Height at Initial Transplant Over Time, by Year of Transplant and Age at Transplant 6-6 Section 7 Exhibit 7.1 Hospitalization Days During the First Post-Transplant Month, by Year of Transplantation and Donor Source 7-4 Exhibit 7.2A Transplant Month Hospitalization 7-5 Exhibit 7.2B Transplant ( ) Month Hospitalization 7-6 Exhibit 7.2C Transplant ( ) Month Hospitalization 7-7 Exhibit 7.3A Exhibit 7.3B Hospitalization Results for Patients with Functioning Grafts in Specified Follow-up Periods (Living Donor Transplants) 7-8 Hospitalization Results for Patients with Functioning Grafts in Specified Follow-up Periods (Cadaver Donor Transplants) 7-9 Exhibit 7.4 Selected Characteristics of Transplants with Malignancy 7-10 Exhibit 7.5A Percent Patient Survival, by Primary Allograft Source 7-11 Exhibit 7.5B Percent Patient Survival, by Era and Primary Allograft Source 7-11 Exhibit 7.6A Exhibit 7.6B Percent Patient Survival of Primary Transplants, by Age at Transplantation Living Donor 7-12 Percent Patient Survival of Primary Transplants, by Age at Transplantation Cadaver Donor 7-12 Exhibit 7.7 Causes of Death Following Index Renal Transplantation 7-13 iv

9 Section 8 Exhibit 8.1 Dialysis Patient Demographics 8-4 Exhibit 8.2 Number and Percent Distributions of Patient Race/Ethnicity, by Dialysis Modality and Age at Initiation 8-7 Exhibit 8.3 Post Initiation (1 Month and 12 Months) Concomitant Drug Therapy 8-8 Exhibit 8.4 Post Initiation (24 Months and 36 Months) Concomitant Drug Therapy 8-9 Exhibit 8.5 Baseline Education Status 8-10 Exhibit 8.6 Baseline Education Status, by Race 8-11 Exhibit 8.7 Baseline Education Status, by Age 8-12 Exhibit 8.8 Percent Full-Time School Attendance 8-13 Exhibit 8.9 Percent Patient Survival, by Age at Dialysis Initiation 8-14 Exhibit 8.10 Causes of Death Following the Index Course of Dialysis 8-15 Section 9 Exhibit 9.1A Modality Initiation and Termination 9-4 Exhibit 9.1B Termination Reasons for Non-Transplanted Patients by Vintage 9-5 Exhibit 9.2A Peritoneal Dialysis Access 9-6 Exhibit 9.2B Peritoneal Access Data by Vintage 9-7 Exhibit 9.3 Catheter Characteristics for Peritoneal Dialysis Accesses 9-8 Exhibit 9.4A Hemodialysis Access 9-9 Exhibit 9.4B Hemodialysis Access Data by Vintage 9-10 Exhibit 9.5 Frequency Distribution of Dialysis Access Status, by Selected Characteristics 9-11 Exhibit 9.6 Reasons for Change of Modality, by Selected Characteristics 9-12 Exhibit 9.7 Time to Dialysis Termination for Index Cases 9-13 Exhibit 9.8 Exhibit 9.9 Time to Dialysis Termination for Index Cases, by Age and Race/Ethnicity 9-14 Time to Dialysis Termination for Index Cases, by PD Catheter Characteristics 9-15 Exhibit 9.10 Time to Dialysis Termination for Index Cases, by HD Access 9-16 v

10 Exhibit 9.11 Time to Dialysis Termination for Index Cases, by Reason for Termination 9-17 Exhibit 9.12 Selected CAPD and APD Patient Demographics 9-18 Exhibit 9.13 Exhibit 9.14 Exhibit 9.15 Time to Dialysis Termination for Selected CAPD/APD Cases, by Modality 9-19 Time to Transplantation and Change of Modality for Selected CAPD/APD Cases, by Modality 9-20 Time to First Peritonitis Episode For Selected CAPD/APD Cases, by Modality 9-21 Section 10 Exhibit 10.1 Percent EPO Use, by Months on Dialysis 10-3 Exhibit 10.2 Percent EPO Use at Baseline (Day 30) 10-4 Exhibit 10.3 Route and Frequency of EPO Administrations 10-5 Exhibit 10.4 Mean EPO Dose (Units/Kg/Week) 10-6 Exhibit 10.5 EPO Frequency (%) at 6 Months, by Modality and Age at Dialysis Initiation 10-7 Exhibit 10.6 Distribution of Hematocrit at 6 Months, by EPO Use 10-7 Exhibit 10.7 Mean and Median Hematocrit Levels at 6 Months, by EPO Use 10-7 Section 11 Exhibit 11.1 Peritoneal Dialysis at Follow-up 11-4 Exhibit 11.2 Number and Percent of Peritonitis Episodes, by Age 11-5 Exhibit 11.3 Peritonitis Infection Rates, by Age and Catheter Characteristics 11-6 Exhibit 11.4 Time to First Peritonitis Infection 11-7 Exhibit 11.5 Time to First Peritonitis Infection, by Age at Peritoneal Dialysis Initiation 11-7 Exhibit 11.6 Time to First Peritonitis Infection, by Catheter Access Characteristics 11-8 Exhibit 11.7 Peritoneal Dialysis Access Revision Exhibit 11.8 Hemodialysis at Follow-up Exhibit 11.9 Hemodialysis Access Revision vi

11 Exhibit Time to Cadaver Transplantation, by Era Exhibit Time to Cadaver Transplantation, by Age Exhibit KT/V by Modality, Age, Race, Visit and Baseline BMI Exhibit URR for Hemodialysis Patients by Age, Race, Visit and Baseline BMI Section 12 Exhibit 12.1 Exhibit 12.2 Exhibit 12.3 Exhibit 12.4 Mean (SE) Height Z-Scores, by Selected Characteristics and Times Following Dialysis Initiation 12-3 Mean (SE) Weight Z-Scores, by Selected Characteristics and Times Following Dialysis Initiation 12-4 Mean Change from Baseline (with SE) in Standardized Height and Weight Scores, by Age, at Times Following Dialysis Initiation Month Growth Data, for rhgh-treated and Untreated Short Control (z < -1.88) and All Control Patients by Age 12-7 Section 13 Exhibit 13.1A CRI Patient Characteristics 13-3 Exhibit 13.1B CRI Diagnoses 13-4 Exhibit 13.1C CRI Diagnoses by Race and Gender 13-5 Exhibit 13.1D CRI Patient Education Status 13-6 Exhibit 13.2 Age at CRI Registration 13-7 Exhibit 13.3 Primary Diagnosis, by Race and Age 13-8 Exhibit 13.4 Percent Distribution of Baseline Tanner Stage, by Age at CRI Registration 13-9 Exhibit 13.5 Mean Baseline Laboratory Measurements Exhibit 13.6 Exhibit 13.7 Exhibit 13.8 Mean Baseline Laboratory Measurements, by Year of CRI Registration Baseline Concomitant Drug Therapy, by Year of CRI Registration Baseline Medical Events History, by Year of CRI Registration (Percent) Exhibit 13.9 Baseline Renal Function, by Age at CRI Registration Exhibit Mean (and SE) Baseline Height, Weight, SDS and BMI vii

12 Exhibit 13.11A Baseline Height SDS, by Age at CRI Registration Exhibit 13.11B Baseline Weight SDS, by Age at CRI Registration Exhibit Baseline Renal Function, by Height Z-Score Exhibit Baseline Renal Function, by Height Z-Score and Age at Entry Exhibit Baseline Renal Function, by Height SDS and Age at Entry Section 14 Exhibit 14.1 CRI Termination Summary 14-3 Exhibit 14.2 Frequency and Percent CRI Termination, and Reason for Termination by Selected Patient Characteristics 14-4 Exhibit 14.3 Risk of Progression to ESRD (Transplant and Dialysis Initiation) 14-6 Exhibit 14.4 Progression to ESRD 14-7 Exhibit 14.5 Exhibit 14.6 Progression to ESRD, by Baseline Calculated Creatinine Clearance (ml/min/1.73 m 2 ) 14-7 Progression to ESRD, by Race, Gender, Age at Entry, Primary Diagnosis, and Baseline Laboratory Results 14-8 Exhibit 14.7 Progression to ESRD Due to Transplantation and Dialysis Initiation Section 15 Exhibit 15.1 CRI Follow-up Data 15-5 Exhibit 15.2 Exhibit 15.3 Exhibit 15.4 Exhibit 15.5 Exhibit 15.6A Mean (+SE) Height Z-Score, by CRI Visit and Selected Baseline Characteristics 15-6 Mean Change from Baseline (+SE) in Height Z-Score, by CRI Visit and Selected Baseline Characteristics 15-7 Mean (+SE) Weight Z-Score, by CRI Visit and Selected Baseline Characteristics 15-8 Mean Change from Baseline (+SE) in Weight Z-Score, by CRI Visit and Selected Baseline Characteristics 15-9 Serum Creatinine (mg/dl) and Calculated Creatinine Clearance (ml/min/1.73 m 2 ): Means and Changes from Baseline (+SE), by Age at Entry Exhibit 15.6B Schwartz Calculated Clearance by Primary Diagnosis Exhibit 15.6C Delta Schwartz Calculated Creatinine Clearance by Primary Diagnosis viii

13 Exhibit 15.7A Exhibit 15.7B Exhibit 15.8A Exhibit 15.8B Exhibit 15.9 Exhibit Exhibit Month Growth Data and Renal Function Data, for rhgh Treated and Untreated Short Control (z < -1.88) and Control Patients Month Growth Data and Renal Function Data, for rhgh Treated and Untreated Short Control (z < -1.88) and Control Patients Excluding 0-1 Year Old Patients Month Growth and Renal Function Data, for rhgh Treated and Untreated Short Control (z < -1.88) and Control Patients Month Growth and Renal Function Data, for rhgh Treated and Untreated Short Control (z < -1.88) and Control Patients Excluding 0-1 Year Old Patients Growth Hormone Utilization for All Age-Sex-Appropriate CRI Patients with Height Z-Score of or Worse, and Tanner Stage I, II, III at the Baseline, or 6-Month, or 12-Month Visit Growth Hormone Utilization for All Age-Sex-Appropriate CRI Patients with Height SDS of or Worse, and Tanner Stage I, II, III at the Baseline, and 6-Month, and 12-Month Visits Growth Hormone Utilization for Current Age-Sex-Appropriate CRI Patients with Height SDS of or Worse, and Tanner Stage I, II, III at the Most Recent Completed Visit in ix

14

15 I. INTRODUCTION

16

17 Introduction INTRODUCTION The North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) is a research effort organized in At the outset of the study, the operational objective of this group was to obtain the voluntary participation of all renal transplant centers in the United States and Canada in which multiple (>4) pediatric patients received renal allografts annually. Scientific objectives included capture of information about current practice and trends in immunosuppressive therapy with an ultimate goal of improving care of pediatric renal allograft recipients in North America. In 1992, the study was expanded to include pediatric patients who receive maintenance hemodialysis or peritoneal dialysis therapy. In 1994, data collection began on patients with chronic renal insufficiency (CRI), defined as a Schwartz calculated creatinine clearance 75 ml/min/1.73 m 2. Now, not only do we hope to register and follow greater than 80% of the children receiving renal allografts in the United States and Canada, but to study the clinical course and natural history of patients with renal dysfunction and to continue following these patients as they move among the end-stage renal disease (ESRD) therapeutic modalities, thus allowing the NAPRTCS to become a complete ESRD patient data system. The NAPRTCS has three functioning organizational bodies: the Clinical Coordinating Center, the Data Coordinating Center, and the participating Clinical Centers. Appendix A details the structure and members of the Coordinating Centers and the participating Clinical Centers are listed in Appendix B. This report summarizes data received at the Data Coordinating Center through December 15, We continue to be particularly pleased and grateful for the enthusiastic response of the volunteer clinical centers, without which this project could not be successful. At the outset of NAPRTCS, "children" were defined as patients who had not yet attained their 18th birthday at the time of their index transplant. The index transplant is defined as the first transplant reported to NAPRTCS during the study period. When the study expanded in 1992 to include maintenance dialysis patients, the age criterion was expanded to include patients who had not yet attained their 21st birthday at the time of index transplant or at the time of index initiation of dialysis, whichever came first. The expanded age criterion was adopted for CRI patients. Data submission for the study is organized to enable analysis of both patient and event characteristics. Among transplant patients, for example, we are interested in graft survival, 1

18 Introduction morbidity, and the relationships that these endpoints have to patient characteristics such as race/ethnicity, sex, and primary renal disease, and to transplant (i.e., event) characteristics such as age at transplantation, donor source, immunosuppressive treatment, and HLA antigen mismatches. Analogous patient and event characteristics are defined in both the CRI and dialysis populations. As data have matured, it has been our intent to design special studies that focus on issues such as quality of life, rehabilitation, physical and mental development, and other questions of interest for particular patient subgroups. In this manner, the study has served and continues to serve as a resource to investigators whose research activities are consistent with the goals and objectives of the program. A list of special studies and analyses is shown in Appendix C. Transplantation follow-up status forms are submitted 6 months following transplant and every 6 months thereafter. For dialysis, follow-up status forms are submitted 30 days after initiation, 6 months after initiation, and every 6 months thereafter. CRI follow-up status forms are submitted at 6-month intervals following the initial reported clinic visit. As of database closure for this report, over 14,500 patients had been registered in NAPRTCS, as shown in the table below. Of these patients, data have been reported to all three registries (CRI, dialysis, and transplantation) for 684. Registry-specific sample sizes can be determined by summing the subgroup totals. For example, the number of transplant patients 8,435 is given by 4, , These data do not necessarily represent a complete accounting of a patient s clinical course: a patient may have received care for his CRI at a NAPRTCS center, received maintenance dialysis at a non-naprtcs center, and rejoined the study when transplantation was performed at a NAPRTCS center. NAPRTCS PATIENT REGISTRATIONS N % All Patients 14, CRI only Dialysis only Transplant only CRI and dialysis CRI and transplant Dialysis and transplant 3,971 1,641 4, , CRI, dialysis, and transplant

19 Introduction Forms have been submitted for 9,243 renal transplants: 8,435 are for index transplants (i.e., first transplant reported to registry) while 808 represent additional reported transplants in the same patient since the study's start on January 1, The 8,435 index transplants are comprised of 4,181 cases where transplantation was the initial reported modality and 4,254 cases where transplantation occurred subsequent to an initial report of patient registration in the dialysis (n=2,833) or CRI (n=1,421) registries. Modality initiation forms have been submitted for 7,357 independent courses of dialysis. An independent course of dialysis therapy is defined to have occurred when a patient is maintained on a given modality for 30 or more days. Of these, 5,641 represent index initiations and 1,717 are for initiations subsequent to the index course. The 5,641 index dialysis courses are comprised of 3,910 cases where dialysis is reported as the initial therapy and 1,731 cases of dialysis initiation subsequent to failure of the index graft (n=638) or termination of CRI status (n=1,136). Initial CRI status forms have been submitted for 5,927 patients. In NAPRTCS, patients are eligible for the chronic renal insufficiency component if, at the first reported clinic visit, the Schwartz calculated creatinine clearance is 75 ml/min/1.73 m 2 or lower. In total, we have received a CRI Termination Form for 2,534 of the 5,927 CRI patients. This report summarizes both patient-level and therapy-level data. In general, descriptive information will focus on the transplant or dialytic modality as the unit of observation. Variables pertinent to the patient (e.g., sex, race, primary diagnosis) will use the number of patients as the denominator. Formal analysis of failure times patient and graft survival and rejection-free intervals include only the first transplant during the study period (the index transplant) for each patient. Occasional missing information on individual characteristics results in the analysis of slightly different subgroups. Continued capture of this information is part of the ongoing data collection process. In addition to the registry components, NAPRTCS initiated its first randomized prospective clinical trial (Protocol IN01) in 1995, the first ever controlled clinical trial of OKT3 induction therapy in children and adolescents. Nested within the primary random assignment to the OKT3 or No OKT3 groups, patients were randomized to receive either Sandimmune or Neoral maintenance cyclosporine therapy. Randomized prospective trials of growth hormone have been performed: one was designed to evaluate the post transplant use of recombinant human growth hormone (rhgh) therapy and the second was a study of rhgh therapy in pediatric dialysis patients. In the transplant 3

20 Introduction study, patients were randomized to standard dose (.05/mg/kg/day) therapy or a delayed treatment control group. After the initial no treatment period of 12 months, control group patients received rhgh therapy for the duration of the study which is a total of 42 months. In the dialysis study, all patients receive standard dose rhgh therapy during the first 12 months, after which patients are randomized either to continue on standard dose therapy or to receive a double dose (.10/mg/kg/day). Patients continued on their "randomized" dose for an additional 12 months. Through the collaborative Clinical Trials in Pediatric Transplantation effort sponsored by the NIAID, NAPRTCS sites have completed enrollment into a large double-blind, randomized trial to evaluate potential to withdraw steroid therapy in transplant patients. Increased accrual to such studies is an important current group objective. 4

21 II. TRANSPLANTATION

22

23 Transplant SECTION 1: TRANSPLANT PATIENT CHARACTERISTICS Patient and transplant characteristics are summarized in Exhibit 1.1 for the 18-year history of the cooperative study. Because of reporting lags, annual accrual totals are still likely to increase, particularly for the later years. The number of transplants for 2004 however has increased by 530 since the previous year s report. As of database closure for this report, 9,243 renal transplants had been reported for 8,435 pediatric patients. This represents 530 new transplants and 496 patients with their first registry transplant since the last report. The percentage of males in the registry, about 59%, has been relatively constant over time. White patients comprise 62% of the cohort, black patients 16%, and Hispanic patients 16%. The percentage of white patients in a given year has decreased from a high of 72% in 1987 to under 55% in There had been a steady increase in the percent of living donors: in 1998, living donation has accounted for about 58% of transplants with living donations peaking at 64% in 2002, compared to 43% in the first four years of the registry. However, the percentage has been under 60% in the last 2 years. Fifty-two percent of all allografts have come from a living donor. Since the study s initiation, fewer transplants have been reported over time that involve young recipients (<6 years old) or young cadaver donors (<10 years old). While the percentage decrease in recipients <6 years old has been gradual in 2000 and 2001 young recipients accounted for 18% and 21% of all transplants, compared to 25% in 1987 the decline in the use of young donors (<10 years old) has been more precipitous, resulting in a percentage point decrease from 38% in 1988 to 14% in 1999 and 6% in Recipient history is further characterized in Exhibit 1.2. The most common primary diagnoses remain as obstructive uropathy and aplastic/hypoplastic/dysplastic kidneys, each present in about 16% of patients. Focal segmental glomerulosclerosis (FSGS) is the third most common (11%) and continues to be the most prevalent acquired renal disease. The five most frequent diagnoses, excluding unknown and other diagnoses, total 52% of the cases, while the remaining diagnoses are each present in no more than 3% of patients. A diagnosis was established for 94% of patients, while biopsy or nephrectomy confirmation of diagnosis is known not to have occurred in 44% of patients. The distributions of the five most prevalent diagnoses vary between black and white patients. For blacks, FSGS is most prevalent (23%), followed by obstructive uropathy (15%), aplasia/hypoplasia/dysplasia (14%), chronic glomerulonephritis (GN) (4%), and SLE nephritis (4%). The prevalences of cystinosis, reflux nephropathy, and hemolytic uremic syndrome were under 2% among black transplant patients. Among whites, however, the order of the five most prevalent 1-1

24 Transplant diagnoses is: obstructive uropathy (17%), aplasia/hypoplasia/dysplasia (17%), FSGS (9%), reflux nephropathy (6%), and medullary cystic disease (4%). The relative order of these prevalent primary diagnoses among Hispanics is similar to that for white patients. At the time of their index transplant, 10% (827/8,435) of patients were receiving their second (or greater) transplant. Twenty-five percent of primary transplants were preemptive, as these patients had never received maintenance dialysis (Exhibit 1.3). The rate of preemptive transplantation differs significantly (p<0.001) between recipients of living (33%) and cadaver (13%) source organs; between males (28%) and females (20%); among age groups, with rates of 20%, 24%, 28%, 23%, and 21% for recipients 0-1, 2-5, 6-12, 13-17, and years old; and across races with whites, blacks, Hispanics, and other races having preemptive transplantation rates of 30%, 14%, 16%, and 16%, respectively. Immediately prior to the primary transplant, the percentages of patients maintained exclusively on hemodialysis and peritoneal dialysis were 29.8% and 39.4%. At the time of primary transplant few spleens had been removed (<1%) and all native renal tissue had been removed in 23% of patients; transplanted grafts have been removed in 37.1% of the index nonprimary transplants (Exhibit 1.3). Exhibit 1.4 details recipient age at transplant. Of the 89 transplants occurring in children younger than 12 months old, there were 5, 21, and 61 transplants, respectively, within the 3-5, 6-8 and 9-11 months age categories, and two were less than 3 months. Only 29 infant transplants have been performed since 1996, six in 1996, three in 1997, three in 1998, five in 1999, one in 2000, four in 2001, six in 2002 and one in 2004 although these numbers may increase as enrollment reports increase. In Exhibit 1.5, it is observed that the sex distribution is most unbalanced in the youngest age groups where 70% of 0-1 and 66% of 2-5 year old patients are male; the distribution is more even among adolescents. This is due to the fact that males comprise the majority of the aplasia/hypoplasia/dysplasia (62%) and obstructive uropathy (86%) diagnoses (see Exhibit 1.6) and the relative incidence of these diagnoses decreases with age. Forty percent of male patients fall into these two diagnostic categories, compared to 21% of females. The contrast is particularly steep in the obstructive uropathy group, a diagnosis shared by 23% of the males, but only 6% of females. Exhibit 1.6 provides for each primary diagnosis the percentages of patients who are male, white race, and known not to have had a biopsy or nephrectomy confirmation of diagnosis. Of transplant registrants with FSGS, 51% are white. Systemic lupus erythematosis is predominantly a disease of females (82%) with the female-specific race distribution given by 25% white, 39% black, and 25% 1-2

25 Transplant Hispanic. The percentages of patients without a histologically confirmed tissue diagnosis are 71%, 69%, and 69% in aplastic/hypoplastic/dysplastic, obstructive uropathy, and reflux nephropathy patients, respectively. The comparable rates for FSGS, hemolytic uremic syndrome, and lupus nephritis are 6%, 47%, and 4%. Exhibit 1.7 categorizes primary diagnoses as either FSGS, GN, structural or other and demonstrates how these distributions differ according to age at transplant. GN is comprised of the following primary diagnoses (chronic glomerulonephritis, idiopathic crescentic glomerulonephritis, mebranoproliferative glomerulonephritis Type I and Type II, SLE nephritis, Henoch-Schonlein nephritis, Berger s (IgA) nephritis, Wegener s granulomatosis, and membranous nephropathy. Structural diagnoses (prune belly, reflux nephropathy and aplasia/hypoplasia/displasias) account for the largest proportion of primary diagnoses among children ages 5 and under; whereas, GN diagnoses are more prevalent with increasing age. 1-3

26 Transplant EXHIBIT 1.1 PATIENT REGISTRATIONS, TRANSPLANTS, AND SELECTED CHARACTERISTICS, BY YEAR OF REGISTRATION %Male %White %Living Donor %Recipient age <6 yrs %CAD donor age <10 yrs PERCENT TRANSPLANT YEAR 1987 '88 ' '91 '92 '93 '94 '95 '96 '97 '98 ' '01 '02 '03 '04 Total No. of Pts No. of Tx

27 Transplant EXHIBIT 1.2 RECIPIENT AND INDEX TRANSPLANT CHARACTERISTICS N (8435) % (100.0) Sex Male Female Race White Black Hispanic Other Primary Diagnosis Obstructive uropathy Aplasia/hypoplasia/dysplasia Focal segmental glomerulosclerosis Reflux nephropathy Chronic glomerulonephritis Polycystic disease Medullary cystic disease Hemolytic uremic syndrome Prune Belly Congenital nephrotic syndrome Familial nephritis Cystinosis Idiopathic crescentic glomerulonephritis Membranoproliferative glomerulonephritis - Type I Pyelo/interstitial nephritis SLE nephritis Renal infarct Berger's (IgA) nephritis Henoch-Schonlein nephritis Membranoproliferative glomerulonephritis - Type II Wilms tumor Drash syndrome Wegener's granulomatosis Oxalosis Membranous nephropathy Other systemic immunologic disease Sickle cell nephropathy Diabetic glomerulonephritis Other Unknown

28 Transplant EXHIBIT 1.3 TRANSPLANT CHARACTERISTICS N % Total Transplants Index Transplants Primary Transplants Repeat Transplant Maintenance Dialysis Immediately Prior to Transplant Hemodialysis only Peritoneal dialysis only Primary Transplant Preemptive Splenectomy Naive Tissue Removed Index Non-primary Transplants Prior Transplants Removed

29 Transplant EXHIBIT 1.4 AGE AT TRANSPLANTATION N (9243) % (100) Age at Transplantation Age Grouping >

30 Transplant EXHIBIT 1.5 AGE AT INDEX TRANSPLANT BY PATIENT'S SEX, RACE, AND DIAGNOSIS [Numbers in Table are Percents] Age at Index Transplantation Total (N=8435) 0-1 (N=474) 2-5 (N=1276) 6-12 (N=2871) (N=3251) >17 (N=560) Gender Male Female Race White Black Hispanic Other Diagnosis Renal plasias Obstructive uropathy Other Focal segmental glomerulosclerosis

31 Transplant EXHIBIT 1.6 SEX, RACE, AND BIOPSY DISTRIBUTIONS, BY PRIMARY RENAL DIAGNOSIS Diagnosis N % Not % Male % White Biopsied Total Diagnosis Obstructive uropathy Aplasia/hypoplasia/dysplasia Focal segmental glomerulosclerosis Reflux nephropathy Chronic glomerulonephritis Polycystic disease Medullary cystic disease Hemolytic uremic syndrome Prune Belly Congenital nephrotic syndrome Familial nephritis Cystinosis Idiopathic crescentic glomerulonephritis Membranoproliferative glomerulonephritis - Type I Pyelo/interstitial nephritis SLE nephritis Renal infarct Berger's (IgA) nephritis Henoch-Schonlein nephritis Membranoproliferative glomerulonephritis - Type II Wilms tumor Drash syndrome Wegener's granulomatosis Oxalosis Membranous nephropathy Other systemic immunologic disease Sickle cell nephropathy Diabetic glomerulonephritis Other Unknown

32 Transplant EXHIBIT 1.7 PRIMARY DIAGNOSIS BY AGE FSGS GN Other Structural Percent >

33 SECTION 2: DONOR HISTORY AND ANTIGEN MISMATCHES NAPRTCS 2005 Transplant As described in Exhibit 2.1, 48% of all transplants have involved a cadaver source, 42% came from a parent, with the remaining 10% coming from other living donors. Parents comprise 81% of living donors: a cross-classification of parent and child sexes (n=3,569 pairs with complete data) reveals that mothers comprise the majority of parent-donors (56%), fathers donate to sons 63% of the time, while mothers make 60% of their donation to sons (p=0.044). There have been 335 transplants between siblings, and 163 live-donor grafts have been from donors under the age of 21. Thirteen living donors were under 18 years of age: 12 were transplants between siblings and 1 was a transplant from parent to child. Between siblings, the numbers of 3-, 4-, 5-, and 6-antigen matches were 1, 2, 2, and 7, respectively. The number of unrelated living donors has increased from an average of 3 per year in to 17 per year since then. Among cadaver transplants, 67 (1.6%) have come from donors less than 24 months old and 1063 (23.9%) from donors who were between 2 and 12 years of age; the use of cadaver donors <10 years old has declined since the study s start (see Exhibit 1.1). Prior to 1992, infant donors comprised 2.9% (42/1,466) of cadaver donor sources, compared to 0.9% (25/2,711) in transplants between 1991 and Thirteen percent of cadaver allografts were preserved by machine perfusion and 69% had cold ischemia times of 24 hours or less, with 17 (0.3%) exceeding 48 hours. The maximum cold time was 64.5 hours. Donor-specific transfusions were performed in 7% of living donor grafts but this procedure has been used only occasionally since The total number of random transfusions given to recipients differed by donor type: 48% of living donor graft recipients and 32% of cadaver graft recipients had zero previous transfusions, while 14% and 29%, respectively, had more than five transfusions. The percent of patients without prior random transfusions has increased from 17% in 1987 (27% living and 10% cadaver donor recipients) to 65% in 2004 (67% living and 62% cadaver). Time trends in the utilization of donor-specific and random transfusions are provided in Exhibit 2.2. To date, there have been 34 confirmed transplants across ABO blood group compatibility barriers out of 8,564 transplants with complete blood group data; there are 25 O recipient/a donor pairs, 2 O recipient/b donor pair, 4 B recipient/a donor pairs, 1 B recipient/ab donor pair, and 2 A recipient/b donor pair. A special analysis of an early cohort of these patients concluded that pediatric kidney transplantation across ABO compatibility barriers is an uncommon practice, but suggested based on preliminary experience that such transplants involving recipients whose anti-a titer history is 2-1

34 Transplant low (1:4) are associated with satisfactory graft outcome and are deserving of further study. Overall, 88% (7,501/8,564) of donor and recipient blood types were identical. Whereas blood group O is present in 56% of donors and 47% of recipients, blood group AB is present in 1.4% of donors and 4.0% of recipients. Histocompatibility antigen data are shown in Exhibit 2.3. We count an allele as matching only if identical known alleles are reported for both donor and recipient. Among the living donor transplants, 76% had at least one match at each of the A, B, and DR loci, and there were mismatches at all 6 A, B, and DR loci for 13% of cases. No matches in either the B or DR loci occurred in 36% of the transplants from cadaver source donors; a single locus match (of B and DR) occurred in 32%. Known matches of all 6 A, B and DR alleles occurred in 2.5% of cadaver source transplants and in 3.5% of living donor source transplants. Exhibit 2.4 compares donor sources with varying ages at transplant. Children under 5 years of age are more likely to receive a transplant from a living donor rather than a cadaver donor. For children ages 6-12, the proportion receiving living donor transplants is similar to the proportion receiving cadaver donor transplants. However, children 13 years of age are more likely to receive a cadaver donor transplant. 2-2

35 Transplant EXHIBIT 2.1 DONOR INFORMATION N (9243) % (100.0) Donor Source Live donor/parent Live donor/sibling Live donor/other related Live donor/unrelated Cadaver Donor Age Living Cadaver > Cadaver Source Transplants Machine Perfusion Used Cold Ischemia Time < 24 hours > 24 hours

36 Transplant EXHIBIT 2.2 USE OVER TIME OF DONOR-SPECIFIC AND RANDOM BLOOD TRANSFUSIONS Living Donor 0 Random transfusions 1-5 Random transfusions >5 Random transfusions Donor-specific transfusions PERCENT TRANSPLANT YEAR Cadaver Donor 0 Random transfusions 1-5 Random transfusions >5 Random transfusions PERCENT TRANSPLANT YEAR 2-4

37 Transplant EXHIBIT 2.3 PERCENT HLA MISMATCHES HLA-A Living (n=4801) Donor Source Cadaver (n=4427) HLA-B HLA-DR HLA-B and -DR HLA-A, -B, and -DR

38 Transplant EXHIBIT 2.4 AGE AT TRANSPLANT AND DONOR SOURCE PERCENT Living Donor Cadaver Donor > 17 AGE (years) 2-6

39 Transplant SECTION 3: THERAPY The NAPRTCS collects information on post-transplant immunosuppressive medications and dosages at Day 30, Month 6, and every six months thereafter. In addition, a record of the date of initiation and dosages of immunosuppressive medication used during the first post-transplant month is collected. Detailed description of pre-operative immunosuppressive therapy is not collected, but it was employed in 50% of living donor transplants. The frequency of use among all recipients had decreased from 48% in 2001 to 40% in Because of the changes in therapy in recent years, analyses are restricted to more recent transplant (>1995). Exhibit 3.1 details immunosuppressive medication data for transplants in 1996 and beyond for the first 30 days post-transplant therapy. Note that the frequency of use of various drugs ranges from 9% (of transplants) for sirolimus to 91% for prednisone. Methylprednisolone and azathioprine, when used, were typically initiated on the day of operation. Polyclonal antibody ATG was used in 16% of living donor and 25% of cadaver source transplants, while the respective rates of monoclonal antibody usage are 40% and 45%. Cyclosporine was used for 63% of transplants and, of those, 21% began cyclosporine on Day 0, 24% on Day 1, and 40% during Days 2-6. Although early graft failures decrease the number of patients still available for immunosuppressive therapy by Day 30, the percentages being treated with prednisone is relatively stable. Over the month, median doses of prednisone decreased to approximately 1/3 of the initial amount and, median doses of cyclosporine increased by 1.0 mg/kg. The median ATG/ALG course was 7 days. For monoclonal antibody, the median length of course of OKT3 was 9 days; for basiliximab patients, it was 2 days; and for daclizumab recipients, the median course was 5 days. Exhibit 3.2 shows the percentage of week 1 calcineurin inhibitor use by type of induction antibody while Exhibit 3.3 presents the induction antibody use from 1996 to The rate of induction antibody use at transplant or one day post transplant, by transplantation year was as follows: 3-1

40 Transplant PERCENT INDUCTION ANTIBODY, AT TRANSPLANT OR ON 1 DAY POST TRANSPLANT 1996 (n=585) 1997 (n=568) 1998 (n=510) 1999 (n=513) 2000 (n=419) 2001 (n=451) 2002 (n=397) 2003 (n=284) 2004 (n=142) None OKT Basiliximab Daclizumab ATG/ALG Exhibit 3.4 presents immunosuppressive therapy dosages for patients with functioning grafts for selected drug combinations after Median daily prednisone doses decrease over the first 2 years after transplantation, while the percentage of transplanted patients receiving alternate day therapy increases from 6.1% at Month 6 to 13.6%, 25.9%, and 33.0% at Months 12, 24, and 48, respectively. Continued slow increases in alternate day steroid use are observed at 6 years (40%). At 5 years post transplant, 32.7% of living donor versus 40.2% of cadaver donor transplants are reported to receive alternate day steroids. Note that there is little change in the proportion of patients receiving prednisone, cyclosporine, and azathioprine at each time point. Among those receiving cyclosporine, the mean and standard error of the daily milligram per kilogram doses are 7.7±0.09, 6.9±0.09, 6.0±0.08, and 4.6±0.12 at Months 6, 12, 24, and 60, respectively. Exhibit 3.5 shows the marked changes in day 30 post transplant dosing strategies that have been observed in the past years. These are substantially caused by the introduction of new drugs such as mycophenolate mofetil and tacrolimus. Although it has substantially effected the later cohort years, the whole experience of the registry has been minimally affected. Use at Day 30 of combination cyclosporine, prednisone, and azathioprine has declined since , from 30% of living donor and 27% of cadaver organ recipients, to 2% and 1% of transplants, respectively, in The regimen of prednisone, tacrolimus, and mycophenolate mofetil has become more popular. It is used in 39% of living donor and 43% of cadaver organ transplant in , compared to about 9.5% of all transplants in

41 Transplant Approximately 80% of patients receive 3-drug therapy at 6 months post transplant with mycophenolate mofetil replacing azathioprine in recent cohorts. Among transplanted grafts with 30 days function that have occurred since 1996, the following drug utilization rates were observed: PERCENT DRUG UTILIZATION - DAY 30 POST TRANSPLANT 1997 (n=568) 1998 (n=510) 1999 (n=513) 2000 (n=419) 2001 (n=451) 2002 (n=397) 2003 (n=284) 2004 (n=142) Cyclosporine Tacrolimus Mycophenolate Azathioprine Sirolimus Substantial increases in tacrolimus, mycophenolate mofetil, and sirolimus usage are observed, with a significant decrease in azathioprine usage. Azathioprine usage has decreased sharply from 60% in 1996 to 3% in The majority of sirolimus therapy (87%) was initiated within the first two days post-transplant. The mean and median dosages were 4.7 and 4.0 mg/m 2, respectively. Cyclosporine was used in 82% of the 1996 transplants at Day 30, and it continues to show a decline in utilization. Of cyclosporine recipients since 1996 with known formulation, 84% reported use of Neoral. Exhibit 3.6 displays the percentage of patients at selected follow-up time points who were receiving the six most common maintenance regiments since 1995, by graft donor source. Through 3 years, about 35% of the patients received combination immunosuppressives with prednisone, cyclosporine, and MMF, compared to approximately 22% of patients with prednisone, cyclosporine and azathioprine. Note that therapy strategies appear similar for cadaver recipients and live donor recipients. For example, dual therapy with prednisone and cyclosporine or prednisone and tacrolimus is received by similar percentages of recipients from living and cadaver graft donors. Because of the differential graft survival in black and non-black patients, cyclosporine blood levels have been examined. At Day 30 mean median values are within 9 ng/ml for two of the most common measurement methods, HPLC and TDX. For black patients, at 1-year post transplant, 3-3

42 Transplant mean cyclosporine level was 183 ng/ml (versus 168 ng/ml for others); cyclosporine blood levels are shown in the table below. MEDIAN / MEAN ± SE ONE YEAR BLOOD LEVELS (NG/ML) BY RACE/ETHNICITY Method Black Other Cyclosporine HPLC 123/152± /130±2.1 TDX 215/239± /234±3.6 Monoclonal RIA-specific 156/189± /169±3.2 TAC HPLC 5.7/6.3± /10.6±2.5 IMX 5.9/6.2± /6.2±0.3 The percentage of patients receiving concomitant anti-hypertensive, prophylactic antibiotic, and anti-convulsant medications, by donor source, are displayed in Exhibit 3.7. A substantial percentage of transplanted children receive anti-hypertensives and antibiotics throughout the followup period. During the first 3 years, an absolute difference in anti-hypertensive medication usage of about 5 percentage points is observed between cadaver and living donor source recipients. Although the percentage receiving such therapy decreases in the first few years of follow-up, over half of the children are receiving anti-hypertensives throughout the period. Prophylactic antibiotic use decreases for both donor source groups during the first 12 months after transplant. At one year, prophylactic antibiotics are used in 49% of living donor and 44% of cadaver donor source recipients with minimal decreases thereafter. At one year, prophylactic antibiotics are used in 37% of hemolytic uremic syndrome patients and in 37% of those with focal segmental glomerulosclerosis, versus 55% of patients diagnosed with reflux nephropathy and 61% with obstructive uropathy. An anti-convulsant medication was given initially to 7% of the transplant recipients, with a greater frequency observed among recipients of cadaver organs (9.0% vs. 6.0%). 3-4

43 Transplant EXHIBIT 3.1 MEDICATION DATA - FIRST 30 DAYS TRANSPLANTS AFTER 1995 Therapy Percent Treated (n=4010) Median Day of Initiation Median Initial Dose (mg/kg/d) Percent Treated Day 30 (n=3869) Median Day 30 Dose (mg/kg/d) Prednisone Methylprednisolone Cyclosporine Azathioprine Tacrolimus Mycophenolate Mofetil* ATG/ALG Monoclonal Antibody 34 0 OKT Basiliximab Daclizumab Sirolimus** *Median initial and Day 30 daily dose in mg per body surface area were and mg/m 2 /Day respectively. **Median initial dose in mg per body surface area was 3.1 mg/m

44 Transplant EXHIBIT 3.2 WEEK 1 CALCINEURIN INHIBITOR USE, BY INDUCTION ANTIBODY Neither Cyclosporine Tacrolimus PERCENT None OKT3 Basiliximab Daclizumab ATG/ALG EXHIBIT 3.3 INDUCTION ANTIBODY USE, BY YEAR PERCENT None OKT3 Basiliximab Daclizumab ATG/ALG TRANSPLANT YEAR 3-6

NAPRTCS Annual Report

NAPRTCS Annual Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2006 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.

More information

NAPRTCS Annual Report

NAPRTCS Annual Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 27 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section

More information

NAPRTCS Annual Report

NAPRTCS Annual Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 28 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.

More information

Targeted Adverse Event (ADV)

Targeted Adverse Event (ADV) Page 1 of 35 North American Pediatric Renal Trials Collaborative Studies Production Release 5.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0;

More information

Targeted Adverse Event (ADV)

Targeted Adverse Event (ADV) North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0; 06-20-13 1.

More information

Protocol: CRI Registry (CRIPR) Targeted Adverse Event(ADV)

Protocol: CRI Registry (CRIPR) Targeted Adverse Event(ADV) Page 1 of 19 Targeted Adverse Event(ADV) Version: 1.1; 02-03 Adverse Event: 1-Malignancy 2-Avascular necrosis 3-Slipped capital femoral epiphyses 4-Intracranial hypertension 5-Other serious adverse event

More information

Progress in Pediatric Kidney Transplantation

Progress in Pediatric Kidney Transplantation Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas

More information

Targeted Adverse Event (ADV)

Targeted Adverse Event (ADV) North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0; 06-20-13 1.

More information

3/5/18. Background. Registry Reports. Dialysis Registry Update and Future Directions

3/5/18. Background. Registry Reports. Dialysis Registry Update and Future Directions Dialysis Registry Update and Future Directions Annabelle N. Chua, MD March 4, 2018 Background Founded in 1987 as a transplant registry Expanded registry to include dialysis (1992) and CKD (1994) Patient

More information

Chapter 8: ESRD Among Children, Adolescents, and Young Adults

Chapter 8: ESRD Among Children, Adolescents, and Young Adults Chapter 8: ESRD Among Children, Adolescents, and Young Adults The number of children beginning end-stage renal disease (ESRD) care decreased by 6% in 2014, totaling 1,398 (Figure 8.1.a). 9,721 children

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 8: Pediatric ESRD 1,462 children in the United States began end-stage renal disease (ESRD) care in 2013. 9,921 children were being treated for ESRD on December

More information

Access Revision (ACC)

Access Revision (ACC) North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Registry Sequence: Date of Access Revision: Access Revision (ACC) Web Version: 1.0; 1.3; 06-20-13 HEMODIALYSIS

More information

Chapter 6: Transplantation

Chapter 6: Transplantation Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.

More information

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2. Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR

More information

Chapter 7: ESRD among Children, Adolescents, and Young Adults

Chapter 7: ESRD among Children, Adolescents, and Young Adults Chapter 7: ESRD among Children, Adolescents, and Young Adults The one-year end-stage renal disease (ESRD) patient mortality among the 0-4 year age group has declined approximately 41.6% over the past decade.

More information

ESRD Dialysis Prevalence - One Year Statistics

ESRD Dialysis Prevalence - One Year Statistics Age Group IL Other Total 00-04 12 1 13 05-09 5 2 7 10-14 15 1 16 15-19 55 2 57 20-24 170 10 180 25-29 269 14 283 30-34 381 9 390 35-39 583 14 597 40-44 871 20 891 45-49 1,119 20 1,139 50-54 1,505 35 1,540

More information

Protocol: 1st Dialysis Sequence (DIALYA)

Protocol: 1st Dialysis Sequence (DIALYA) Page 1 of 32 North American Pediatric Renal Trials Collaborative Studies Production Release 5.0 [$sitecode] User: Registry Sequence: Date of Access Revision: Access Revision (ACC) Web Version: 1.0; 1.3;

More information

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80% SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney

More information

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent

More information

ESRD Mortality. Causes of CKD in Children. Causes of Late Graft Failure. 5-Year Allograft Survival. All-cause mortality rates, 2005, by age

ESRD Mortality. Causes of CKD in Children. Causes of Late Graft Failure. 5-Year Allograft Survival. All-cause mortality rates, 2005, by age North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Causes of CKD in Children Founded in 1992 78 participating centers in Canada & U.S. 16,339 CKD patients age 0 18 years 9,506 renal

More information

Final Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List

Final Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List OPTN/UNOS Minority Affairs Committee Descriptive Data Request Final Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List Prepared for: Minority Affairs Committee Meeting

More information

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant

More information

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr (Mr) Rohan Malek Dr Wong Hin Seng Dr Fan Kin Sing Dr Rosnawati Yahya Dr S Prasad Menon Dr Tan Si

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party

More information

Epidemiology of CKD in Children

Epidemiology of CKD in Children Epidemiology of CKD in Children Ali Düzova, M.D. Hacettepe University Faculty of Medicine Pediatric Nephrology and Rheumatology Unit Ankara CKD Course 03 June 2011, İstanbul Aim & Plan Causes of CKD in

More information

Pediatric Kidney Transplantation

Pediatric Kidney Transplantation Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida

More information

Chapter IX. Pediatric End Stage Renal Disease. Incidence of Reported Pediatric ESRD

Chapter IX. Pediatric End Stage Renal Disease. Incidence of Reported Pediatric ESRD Annual Data Report Chapter IX T his chapter examines the incidence, prevalence, modalities of treatment, and survival outcomes specific to the national pediatric ESRD population. Children with advanced

More information

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT HISTOPATHOLOGIC DISORDERS AFFECTING THE ALLOGRAFT OTHER THAN REJECTION RECURRENT DISEASE DE NOVO DISEASE TRANSPLANT GLOMERULOPATHY Glomerular Non-glomerular

More information

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr Zaki Morad Mohd Zaher Dato Dr (Mr) Rohan Malek Dr Fan Kin Sing Dr Lily Mushahar Dr Lim Soo Kun Dr

More information

ANNUAL REPORT The Norwegian Renal Registry. (Norsk Nefrologiregister)

ANNUAL REPORT The Norwegian Renal Registry. (Norsk Nefrologiregister) ANNUAL REPORT 21 The Norwegian Renal Registry (Norsk Nefrologiregister) This report will also be available on: http://152.94.12.23/nyreforening/uremiregisteret/esdr.html Correspondence to: Overlege dr.med

More information

Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol

Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN

More information

Steroid Minimization: Great Idea or Silly Move?

Steroid Minimization: Great Idea or Silly Move? Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,

More information

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

More information

North American Pediatric Renal Trials Collaborative Studies Production Release Registration (DEM) Web Version: 1.0; 1.

North American Pediatric Renal Trials Collaborative Studies Production Release Registration (DEM) Web Version: 1.0; 1. Registration (DEM) Web Version: 1.0; 1.4; 06-20-13 1. Does your site participate in the NAPRT CS Registries? 1- No 2- Yes 2. Date of birth: (mm/dd/yyyy) 3. Race/ethnicity: 4. Gender: 1-Male 2-Female 5.

More information

Appendix G Coding: Ethnicity, EDTA Primary Renal Diagnoses, EDTA Causes of Death and Treatment Timeline Modality Codes

Appendix G Coding: Ethnicity, EDTA Primary Renal Diagnoses, EDTA Causes of Death and Treatment Timeline Modality Codes Coding: Ethnicity, EDTA Primary Renal Diagnoses, EDTA Causes of Death and Treatment Timeline Modality Codes G1: Ethnicity coding Ethnicity data is recorded in the clinical information systems in the individual

More information

2015 Children's Mercy Hospitals and Clinics. All Rights Reserved.

2015 Children's Mercy Hospitals and Clinics. All Rights Reserved. Growth van Stralen KJ, et al., Kidney Int, 2014 Blood Pressure Management van Stralen KJ, et al., Kidney Int, 2014 Sodium Losses on PD Infants might need higher UF rate per BSA as compared to adults to

More information

Kidney and Pancreas Transplantation in the United States,

Kidney and Pancreas Transplantation in the United States, American Journal of Transplantation 2006; 6 (Part 2): 1153 1169 Blackwell Munksgaard No claim to original US government works Journal compilation C 2006 The American Society of Transplantation and the

More information

THE KIDNEY AND SLE LUPUS NEPHRITIS

THE KIDNEY AND SLE LUPUS NEPHRITIS THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS

More information

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi

More information

QQuickly take me up into the bright child of your mind. E.E. CUMMINGS, The Enormous Room

QQuickly take me up into the bright child of your mind. E.E. CUMMINGS, The Enormous Room QQuickly take me up into the bright child of your mind. E.E. CUMMINGS, The Enormous Room msix PEDIATrIC ESrD 18 ž 21 ATLAS OF ESRD IN THE UNITED STATES Incident rates of ESRD in children have risen two

More information

Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation

Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery

More information

Kidney Transplantation

Kidney Transplantation Kidney Transplantation Current Kidney Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr Current Kidney

More information

Recurrent Diseases in the Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania

Recurrent Diseases in the Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Recurrent Diseases in the Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Case #1 21-year-old male, was on hemodialysis since September 2005 History of nephrotic

More information

Overview of New Approaches to Immunosuppression in Renal Transplantation

Overview of New Approaches to Immunosuppression in Renal Transplantation Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute

More information

CHAPTER 5 RENAL TRANSPLANTATION

CHAPTER 5 RENAL TRANSPLANTATION CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr. Goh Bak Leong Expert Panel: Dato Dr. Zaki Morad b Mohd Zaher (Chair) Dr. Goh Bak Leong (Co-Chair) Dr. Fan Kin Sing Dr. Lily Mushahar Mr. Rohan Malek Dr. S. Prasad

More information

CHAPTER 14. Renal Transplantation

CHAPTER 14. Renal Transplantation 15th Report of the Malaysian RENAL TRANSPLANTATION CHAPTER 14 Renal Transplantation Editor: Dr. Goh Bak Leong Expert Panel: : Dato Dr. Dato Zaki Dr. Morad Zaik Morad Mohd (Chair) Zaher (Chair) Dr. Goh

More information

Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome

Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome Page 1 of 16 Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome MANUAL OF OPERATIONS VERSION 1.0 March 10, 2016 Page 2 of 16 STUDY PERSONNEL CONTACT INFORMATION Principal

More information

Hasan Fattah 3/19/2013

Hasan Fattah 3/19/2013 Hasan Fattah 3/19/2013 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels

More information

CHAPTER 5. Paediatric Renal Replacement Therapy

CHAPTER 5. Paediatric Renal Replacement Therapy 24th Report of the CHAPTER 5 Paediatric Renal Replacement Therapy Lee Ming Lee Lim Yam Ngo Lynster Liaw Chiew Tung Susan Pee Yap Yok Chin Wan Jazilah Wan Ismail 24th Report of the SECTION A: RRT PROVISION

More information

CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 2007

CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 2007 CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 27 Stephen McDonald Leonie Excell Hannah Dent NEW PATIENTS ANZDATA Registry 28 Report Figure 2.1 Annual Intake of New Patients 23-27 (Number Per Million Population)

More information

Chapter 1. Incidence of End Stage Kidney Disease. Contents:

Chapter 1. Incidence of End Stage Kidney Disease. Contents: Chapter 1 Incidence of End Stage Kidney Disease Contents: Incidence of End Stage Kidney Disease 1-1 Stock and Flow 1-2 Incident patients 1-3 Incident Rates 1-3 Late Referral 1-7 Co-Morbidities 1-9 Primary

More information

A Tolerance Approach to the Transplantation of Vascularized Tissues

A Tolerance Approach to the Transplantation of Vascularized Tissues A Tolerance Approach to the Transplantation of Vascularized Tissues The 9th New Jersey Symposium on Biomaterials Science and Regenerative Medicine October 29-31, 2008 David H. Sachs, M.D. Harvard Medical

More information

Chronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP

Chronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital

More information

Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents

Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human

More information

Literature Review: Transplantation July 2010-June 2011

Literature Review: Transplantation July 2010-June 2011 Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney

More information

Literature Review Transplantation

Literature Review Transplantation Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of

More information

The New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health

The New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting

More information

Tolerance Induction in Transplantation

Tolerance Induction in Transplantation Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent

More information

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Rosnawati Yahya. Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng.

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Rosnawati Yahya. Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng. CHAPTER 5 Editor: Roswati Yahya Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng Contents 5. Stock and Flow of Rel Transplantation Stock and Flow Transplant Rates 5.2 Recipients

More information

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids

More information

Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012.

Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012. http://www.kidney-international.org chapter 6 & 2012 KDIGO Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, 181 185; doi:10.1038/kisup.2012.19

More information

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal

More information

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of

More information

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular

More information

Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients

Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK

More information

kidney OPTN/SRTR 2012 Annual Data Report:

kidney OPTN/SRTR 2012 Annual Data Report: kidney wait list 18 deceased donation 22 live donation 24 transplant 26 donor-recipient matching 28 outcomes 3 pediatric transplant 33 Medicare data 4 transplant center maps 43 A. J. Matas1,2, J. M. Smith1,3,

More information

Chapter 5 PAEDIATRIC RENAL REPLACEMENT THERAPY. Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin

Chapter 5 PAEDIATRIC RENAL REPLACEMENT THERAPY. Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin Chapter 5 PAEDIATRIC RENAL REPLACEMENT THERAPY Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin SECTION A: RRT PROVISION FOR PAEDIATRIC PATIENTS This chapter presents

More information

Transplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital

Transplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital Transplant Options for Patients: Choices and Consequences Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital BC Kidney Days October 6 th 2017 Non contributory Conflict of

More information

Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome

Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome Page 1 of 17 Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome MANUAL OF OPERATIONS VERSION 5.0 August 1, 2017 Page 2 of 17 STUDY PERSONNEL CONTACT INFORMATION Principal

More information

Kidney Transplant. Description

Kidney Transplant. Description Section: Surgery Effective Date: October 15, 2015 Subject: Kidney Transplant Page: 1 of 9 Last Review Status/Date: September 2015 Kidney Transplant Description A kidney transplant involves the surgical

More information

Current status of kidney and pancreas transplantation in the United States,

Current status of kidney and pancreas transplantation in the United States, American Journal of Transplantation 25; 5 (Part 2): 94 915 Blackwell Munksgaard Blackwell Munksgaard 25 Current status of kidney and pancreas transplantation in the United States, 1994 23 Gabriel M. Danovitch

More information

Nephrology Dialysis Transplantation

Nephrology Dialysis Transplantation Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.

More information

This study is currently recruiting participants.

This study is currently recruiting participants. A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting

More information

GUIDELINES ON RENAL TRANSPLANTATION

GUIDELINES ON RENAL TRANSPLANTATION 46 GUIDELINES ON RENAL TRANSPLANTATION T. Kälbe (chairman), M. Lucan, G. Nicita, R. Sells, F.J. Burgos Revilla, M. Wiesel Introduction The number of patients registered as starting end-stage renal disease

More information

Management of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania

Management of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Management of a Recipient with a Failed Kidney Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Disclosures Grant support: Bristol-Myers and Squibb Pharmaceuticals,

More information

Ryszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation

Ryszard Grenda: Steroid-Free Pediatric Transplantation. Early Steroid Withdrawal in Pediatric Renal Transplantation Trends in Transplant. 2011;5:115-20 Ryszard Grenda: Steroid-Free Pediatric Transplantation Early Steroid Withdrawal in Pediatric Renal Transplantation Ryszard Grenda Department of Nephrology, Kidney Transplantation

More information

Vol. 29, pp.585 ~ 589, ml. 1.6 mg/dl 1 MRSA. Table 1 MRI

Vol. 29, pp.585 ~ 589, ml. 1.6 mg/dl 1 MRSA. Table 1 MRI Vol. 29, pp.585 ~ 589, 2001 8 13 10 22 8 7 1 14 49 26.1 6 2 ABO 7 1 400 800 ml 5 4 10 4 3 3 ABO 3 4 5 5 1 3 4 1 0.8 1.6 mg/dl 1 MRSA 10 7 1 10 7 22 40 8 CYA+ AZ+ MP 3 4 7 GSP 4 1 Table 1 23 1 15 11 5 Alport

More information

Date: 23 June Context and policy issues:

Date: 23 June Context and policy issues: Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review

More information

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University

More information

Chapter 2 End-Stage Renal Disease: Scope and Trends

Chapter 2 End-Stage Renal Disease: Scope and Trends Chapter 2 End-Stage Renal Disease: Scope and Trends Chapter 2 End-Stage Renal Disease: Scope and Trends END-STAGE RENAL DISEASE DEFINED The primary functions of the kidney are to remove waste products

More information

Case Presentation Turki Al-Hussain, MD

Case Presentation Turki Al-Hussain, MD Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory

More information

James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant

James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest

More information

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01.

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01. Kidney transplant results in children: progress made, but blacks lag behind Vikas R. Dharnidharka, MD, MPH 1 and Michael E. Seifert, MD 1,2 1 Division of Pediatric Nephrology, Washington University School

More information

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients A Skaro, A LeFever, J Mathew, L Gallon, J Hie, C Hansen, D Stare, G Johnson, J Leventhal

More information

Transplantation in Australia and New Zealand

Transplantation in Australia and New Zealand Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia

More information

For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)

For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH

More information

Case Report 17-Year-Old Boy with Renal Failure and the Highest Reported Creatinine in Pediatric Literature

Case Report 17-Year-Old Boy with Renal Failure and the Highest Reported Creatinine in Pediatric Literature Case Reports in Pediatrics Volume 2015, Article ID 703960, 4 pages http://dx.doi.org/10.1155/2015/703960 Case Report 17-Year-Old Boy with Renal Failure and the Highest Reported Creatinine in Pediatric

More information

PEDIATRIC RENAL TRANSPLANTATION - INDIAN EXPERIENCE

PEDIATRIC RENAL TRANSPLANTATION - INDIAN EXPERIENCE PEDIATRIC RENAL TRANSPLANTATION - INDIAN EXPERIENCE K. Phadke, S. Ballal, K. Venkatesh and S. Sundar* From the Department of Pediatrics, Division of Pediatric Nephrology, Manipal Hospital, Bangalore and

More information

Takashi Yagisawa 1,2*, Makiko Mieno 1,3, Norio Yoshimura 1,4, Kenji Yuzawa 1,5 and Shiro Takahara 1,6

Takashi Yagisawa 1,2*, Makiko Mieno 1,3, Norio Yoshimura 1,4, Kenji Yuzawa 1,5 and Shiro Takahara 1,6 Yagisawa et al. Renal Replacement Therapy (2016) 2:68 DOI 10.1186/s41100-016-0080-9 POSITION STATEMENT Current status of kidney transplantation in Japan in 2015: the data of the Kidney Transplant Registry

More information

European Risk Management Plan. Measures impairment. Retreatment after Discontinuation

European Risk Management Plan. Measures impairment. Retreatment after Discontinuation European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment

More information

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study: An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his

More information

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function

More information

Management of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania

Management of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Management of a Recipient with a Failed Kidney Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Objectives Epidemiology of transplant failure Timing of dialysis

More information

Heart Transplant: State of the Art. Dr Nick Banner

Heart Transplant: State of the Art. Dr Nick Banner Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression

More information

FULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access

FULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access INTRODUCTION ANEMIA TREATMENT hemoglobin levels epo treatment iron treatment FULFILLMENT OF K/DOQI GUIDELINES 2 anemia treatment dialysis therapy vascular access EPO DOSING PATTERNS 4 epo dosing per kg

More information

Chapter 15: Report of the Paediatric Renal Registry 1999

Chapter 15: Report of the Paediatric Renal Registry 1999 Chapter 15: Report of the Paediatric Renal Registry 1999 Prepared by Dr M Lewis Introduction In parallel with the creation of the National Renal Registry, the British Association for Paediatric Nephrology

More information